Accrued API and bulk drug product price true-up current.

No definition available.

Name:	fgen_AccruedApiAndBulkDrugProductPriceTrueUpCurrent
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Acquired in process research and development asset.

+ References

No definition available.

+ Details

Name:	fgen_AcquiredInProcessResearchAndDevelopmentAsset
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the maximum contractual maturity period for available-for-sale securities.

+ References

No definition available.

+ Details

Name:	fgen_AvailableForSaleSecuritiesContractualMaturityPeriod
Namespace Prefix:	fgen_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative arrangement aggregate consideration for milestone and upfront payments.

+ References

No definition available.

+ Details

Name:	fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_CashAndCashEquivalentsAtCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 8A
-URI https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562

+ Details

Name:	us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_LicenseAgreementWithEluminexMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Balance Sheet Components - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jul. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents	$ 155,960,000		$ 155,960,000		$ 171,223,000
Other-than-temporary impairment loss	0	$ 0	0	$ 0
API and bulk drug product price true-up	66,474,000		66,474,000
Acquired In Process Research And Development Asset					35,000,000
Profit share liability	7,361,000		$ 7,361,000		15,857,000
Eluminex [Member]
Schedule of Available-for-sale Securities [Line Items]
Unbilled upfront payment						$ 8,000,000.0
Maximum [Member]
Schedule of Available-for-sale Securities [Line Items]
Contractual maturities of available-for-sale investments			2 years
Foreign subsidiaries [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents	$ 84,400,000		$ 84,400,000		$ 91,200,000